The influence of gender factors in psychiatric treatment

被引:16
作者
Godfroid, IO [1 ]
机构
[1] DIO Godfroid, Psychiagen & Psychiat Res Grp, B-7370 Wiheries, Belgium
来源
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE | 1999年 / 44卷 / 04期
关键词
D O I
10.1177/070674379904400406
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: This paper reviews the literature discussing the influence of gender factors on the efficacy of the most frequently used psychiatric treatments. It recommends taking into account patient gender in order to optimize the treatment efficacy and tolerance. Method: Pharmaceutical and psychotherapeutic treatments as well as other types of therapy (psychosurgery, electroconvulsive therapy [ECT]) are discussed in the overview Each section draws intermediate conclusions. Results: Literature on the subject is scarce and uneven. From a pharmaceutical perspective, gender differences are marked; they affect substance absorption, distribution, metabolism, and elimination. As a result, differences in bioavailability affect efficacy and side effects of antidepressants, neuroleptics, and lithium as well as of hypnotics, sedatives, and anxiolytics. The menstrual cycle and birth-control pills also produce significant interactions. Few studies have discussed the influence of the gender-specific effect on the outcome of psychotherapy. However, some differences might exist, and serious further research is required before repeatable conclusions can be reached. Patient gender does not seem to affect certain physical kinds of treatment such as psychosurgery or ETC as much. Conclusions: Patient gender has a definite influence on the efficacy of the treatment administered. This influence however, is often limited and should be considered for the optimization of treatment response and tolerance. Research in this field of psychiatry should be encouraged.
引用
收藏
页码:362 / 367
页数:6
相关论文
共 62 条
[1]   IMPAIRMENT OF DIAZEPAM METABOLISM BY LOW-DOSE ESTROGEN-CONTAINING ORAL-CONTRACEPTIVE STEROIDS [J].
ABERNETHY, DR ;
GREENBLATT, DJ ;
DIVOLL, M ;
ARENDT, R ;
OCHS, HR ;
SHADER, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 306 (13) :791-792
[2]   IMIPRAMINE DISPOSITION IN USERS OF ORAL-CONTRACEPTIVE STEROIDS [J].
ABERNETHY, DR ;
GREENBLATT, DJ ;
SHADER, RI .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 35 (06) :792-797
[4]  
BAER L, 1995, ARCH GEN PSYCHIAT, V52, P384
[5]   GENDER-ROLE ANALYSIS - A NEGLECTED COMPONENT OF PSYCHOLOGICAL-ASSESSMENT [J].
BROWN, LS .
PSYCHOTHERAPY, 1986, 23 (02) :243-248
[6]  
CHAMBERLAIN S, 1990, AM J PSYCHIAT, V147, P907
[7]   PIMOZIDE IN THE TREATMENT OF NEWLY ADMITTED SCHIZOPHRENIC-PATIENTS [J].
CHOUINARD, G ;
ANNABLE, L .
PSYCHOPHARMACOLOGY, 1982, 76 (01) :13-19
[8]   SEIZURE THRESHOLD IN ELECTROCONVULSIVE-THERAPY (ECT) .2. THE ANTICONVULSANT EFFECT OF ECT [J].
COFFEY, CE ;
LUCKE, J ;
WEINER, RD ;
KRYSTAL, AD ;
AQUE, M .
BIOLOGICAL PSYCHIATRY, 1995, 37 (11) :777-788
[9]   SEIZURE THRESHOLD IN ELECTROCONVULSIVE-THERAPY .1. INITIAL SEIZURE THRESHOLD [J].
COFFEY, CE ;
LUCKE, J ;
WEINER, RD ;
KRYSTAL, AD ;
AQUE, M .
BIOLOGICAL PSYCHIATRY, 1995, 37 (10) :713-720
[10]  
CONRAD CD, 1986, J AM ACAD CHILD PSY, V26, P852